Research statement
I have a broad interest in Molecular Biology and Genetics and I’m excited for the opportunity to conduct research in a clinical environment. My PhD focuses on the correction of a COL17A1 mutation by the use of different CRISPR/Cas9 associated genome editing technologies. COL17A1 encodes Collagen XVII, a transmembrane protein that is crucial for the attachment of the epidermis to the underlying dermis. Mutations within this gene can lead to junctional Epidermolysis bullosa. I hope that my research will contribute to bring genome editing approaches for Epidermolysis bullosa (closer) to the clinic.
Personal interests
In my spare time I like to read, go cycling and play with my two cats (although not enough according to them).
Curriculum Vitae Markus Hierl
Professional career
Since 2022
Scientific associate at the EB House Austria
Education
Since 2022
PhD studies in natural sciences, Paris Lodron University Salzburg
“Ex vivo gene editing strategies for junctional Epidermolysis bullosa”
Working group: Ulrich Koller
2020-2022
Master studies: Medical Biology at the University of Salzburg (with distinction)
Subject of master thesis: Clostridial Collagenase Inhibitors – Enzymatic Characterisation & Crystallisation
Supervisor: Hans Brandstetter
2016-2020
Bachelor studies: Biology, University of Salzburg (with distinction)
2012-2017
Bachelor studies: Philosophy, University of Salzburg
Awards and Fellowships
2020 Performance scholarship – Bachelor Studies Biology
Reviews
- Bischof J, Hierl M, Koller U. Emerging Gene Therapeutics for Epidermolysis Bullosa under Development. International journal of molecular sciences 2024;25:2243.